Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | 0032 | ECE2013 | 15th European Congress of Endocrinology

ea0032p840 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Early and sustained tumour volume reduction and GH/IGF1 control in patients with GH-secreting pituitary macroadenoma primarily treated with lanreotide Autogel 120 mg for 48 weeks: the PRIMARYS study

ea0032p841 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

The benefits of pasireotide in patients with Cushing's disease are not restricted to patients with normalisation of UFC; results from a large, 12-month study

ea0032p842 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Exploration of hand size as a screening tool for acromegaly

ea0032p843 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

The results of sandostatin LAR therapy in acromegalic patients

ea0032p844 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Spanish molecular registry of pituitary adenomas: a multicenter, translational approach aimed at improving patient management

ea0032p845 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Pasireotide LAR and octreotide LAR maintain inhibition of GH and IGF1 in patients with acromegaly: 12-month extension phase of a randomized, double-blind, multicenter, phase III study

ea0032p846 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Characteristics of patients with pituitary gigantism: results of an international study

ea0032p847 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Switching patients with acromegaly from octreotide LAR to pasireotide LAR improves biochemical control: crossover extension to a randomized, double-blind, multicenter, Phase III study

ea0032p848 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Advanced glycation end product associated skin autofluorescence and serum corboxymethyl lysine levels in acromegaly

ea0032p849 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

The prevalence of insufficient test responses in patients with traumatic brain injury compared to healthy controls – results from The Danish National Study on posttraumatic hypopituitarism

ea0032p850 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Endoscopic transsphenoidal approach as a promising surgical option in the treatment of craniopharyngioma

ea0032p851 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

A precocious GH peak at GHRH plus arginine test in GH sufficient short children is predictive of a lower growth velocity

ea0032p852 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

A novel mutation in gonadotropin releasing hormone receptor causing delay in puberty in a sporadic case of isolated hypogonadotropic hypogonadism

ea0032p853 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Evaluation of late-night salivary cortisol during a Phase III study with pasireotide in patients with Cushing's disease

ea0032p854 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Evaluation of long-term pituitary functions after hypoxia due to ventricular arrhythmias: a preliminary report

ea0032p855 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Long-term efficacy of long-acting somatostatin analogues in combination with pegvisomant in 112 acromegaly patients, a retrospective single centre study with follow up for up to 8 years

ea0032p856 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Long-term safety of long-acting somatostatin analogues in combination with pegvisomant in 133 acromegalic patients, a retrospective single centre study with follow up for up to 8 years

ea0032p857 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Similar response to therapy of pituitary adenomas with and without SOX2-expressing cells

ea0032p858 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

The clinical characteristics of pain in patients with pituitary adenomas

ea0032p859 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Genetic and clinical characteristics of Serbian FIPA families

ea0032p860 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Doubled mortality ratio in female patients with non-functioning pituitary adenomas

ea0032p861 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Incidentally discovered pituitary adenomas: single-center experience on 205 patients

ea0032p862 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Clinical diagnostic implications of sequential pattern of dynamic MRI for pituitary microadenoma

ea0032p863 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

How to get surgical remission rates in ACTH- and GH-microadenomas to 100%

ea0032p864 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Moderate hyponatremia is associated with an increased risk of overall mortality: a comprehensive meta-analysis

ea0032p865 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Effects of somatostatin analogues on muscle sympathetic nerve activity in acromegaly

ea0032p866 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Effects of short (12 months) and long (60 months) term treatment with cabergoline on metabolic syndrome and visceral adiposity index in patients with hyperprolactinemia

ea0032p867 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Real world data in acromegaly – a retrospective chart audit

ea0032p868 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Prevalence of escape and lipodystrophy in patients treated with Pegvisomant. A multicenter study

ea0032p869 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

The effect of the ANKK1/DRD2 Taq1A polymorphism on metabolic side effects of dopaminergic treatment in PRL adenomas

ea0032p870 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Incidental haemorrhage in prolactinomas: is it of any clinical significance?

ea0032p871 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Incidence of pituitary adenomas in Western Sweden in 2001–2011

ea0032p872 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Ursodeoxycholic acid role in chronic cholecystitis progression prevention in acromegaly patients receiving somatostatin analogues

ea0032p873 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Relationship between telomere length and dyslipidemia in patients with Cushing's syndrome

ea0032p874 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Factors Affecting Prognosis in a Series of Acromegalic Patients

ea0032p875 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Thirty-day mortality in acute non-surgical patients admitted with hyponatremia

ea0032p876 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Metabolic impact of IGF(CA)19 gene polymorphism on the response to GH therapy in adult GH-deficient (GHD) patients

ea0032p877 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Hypopituitarism after fractionated stereotactic radiation therapy of anterior skull base meningiomas is caused by mass effects, not radiation

ea0032p878 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Role of IGF(CA)19 gene polymorphism in the clinical presentation of acromegaly

ea0032p879 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Relationship between early endocrine alterations and functional outcome in patients with severe brain injury

ea0032p880 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Limitations of basal IGF-1 status reflecting the severity of growth hormone deficiency and predicting response to replacement therapy

ea0032p881 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Effects of gender and body composition on GH response to GHRH+Arg in HIV-lipodystrophic patients: higher rate of GH deficiency in men

ea0032p882 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Obesity in patients with craniopharyngioma seems to be caused by eating disorders rather than changes in mood or activity

ea0032p883 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Correlation of clinical smell test and magnetic resonance imaging of olfactory system in idiopathig hypogonadotropic hypogonadism

ea0032p884 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Diencepephalic syndrome before diagnosis of childhood craniopharyngioma: results of multinational studies on 485 long-term survivors after childhood craniopharyngioma

ea0032p885 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Xanthogranuloma, Rathke‘s cyst, and Childhood Craniopharyngioma: results of prospective multinational studies of children and adolescents with rare sellar malformations

ea0032p886 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Short-term exercise-induced GH response in athletes: differential results for runners and bikers when tested on bicycle

ea0032p887 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Gender determines ACTH recovery after experimental hypercortisolemia in older individuals

ea0032p888 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Levels of prolactin, FSH and LH pool vs single sample determination

ea0032p889 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Tumors with simultaneous hypersecretion of somatotropin and prolactin are associated with earlier diagnosis compared with tumors with isolated hysecretion of somatotropin

ea0032p890 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Macroprolactinomas: dopamine agonists for how long?

ea0032p891 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Role of reversal of hypogonadism on the improvement of metabolic syndrome in male patients with hyperprolactinemia during chronic treatment with cabergoline

ea0032p892 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Measurement of hGH in acromegalic patients under pegvisomant treatment

ea0032p893 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Myeloproliferative neoplasms in patients with acromegaly

ea0032p894 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Familiar panhypopituitarism by a mutation in PROP1: four of seven brothers affected

ea0032p895 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Cushing's disease in children – the effectiveness and complications of transsphenoidal surgery

ea0032p896 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Effect of treatment outcome on co-morbidities of Cushing's disease

ea0032p897 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Serum GH but not IGF1 levels correlate with body composition parameters in both men and women with active acromegaly

ea0032p898 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Receptor expression in craniopharyngiomas causing tumor growth in pregnancy: case report and review of the literature

ea0032p900 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Increased thyroid cancer risk in acromegaly

ea0032p901 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Efficacy and safety of lanreotide in combination with pegvisomant in clinical practice in patients with active acromegaly with monotherapy failure

ea0032p902 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Efficacy and safety of lanreotide in combination with cabergoline in clinical practice in patients with active acromegaly with monotherapy failure

ea0032p903 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Efficacy of hGH treatment in pituitary dwarfism- age does matter

ea0032p904 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Clinical, hormonal and radiological characteristics of a group of primary empty sella patients

ea0032p905 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

The effects of cabergoline treatment on cardiac valves in patients with prolactinoma

ea0032p906 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Treatment with pasireotide LAR normalizes prolactin levels in patients with acromegaly and hyperprolactinemia: randomized, double-blind, 12-month, phase III study

ea0032p907 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Characteristics and outcomes of the Italian subpopulation enrolled in the observational, multicenter hypopituitary control and complications study (HypoCCS)

ea0032p908 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Sleep-apnea and cardiomyopathy in acromegalic patients

ea0032p909 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

PONV prophylaxis alters postoperative cortisol-measurement in transphenoidal pituitary surgery

ea0032p910 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Report of a new case of the novel AIP p.R314W mutation in a Romanian sporadic acromegaly patient

ea0032p911 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

The p.R16H AIP sequence variant is relatively frequent in Romanian sporadic pituitary adenoma patients

ea0032p912 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Prevalance of cancer in acromegaly patients; a single center data

ea0032p913 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Comparison of insulin tolerance test and ACTH stimulation test for evaluation of hypocortisolism in patients with acromegaly

ea0032p914 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Functional hyperprolactinemia in polycystic ovary syndrome: incidence and correlation with hormonal parameters

ea0032p915 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Bone turnover decreases 6 months after acromegaly remission but still remains higher than in healthy population

ea0032p916 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Skin flora in acromegaly

ea0032p917 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Effect of short- and long-term treatment with pasireotide on hemochrome in patients with Cushing's disease

ea0032p918 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Evaluation of QT dispersion at the time of diagnosis and at the end of follow-up in acromegaly patients

ea0032p919 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Transsphenoidal surgery, gamma-knife surgery and diabetes are the factors affecting the quality of life in acromegalic patients

ea0032p920 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

The short synacthen test may be more sensitive than the glucagon stimulation test in assessing the hypothalamic–pituitary–adrenal axis: a retrospective audit

ea0032p921 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Abstract unavailable

ea0032p922 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Characterization of GH-producing pituitary adenomas according to responsiveness to thyrotropin-releasing hormone

ea0032p923 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Tumour volume reduction and GH/IGF1 control with lanreotide Autogel 120 mg every 28 days for treatment-naive acromegalic patients with GH-secreting pituitary macroadenoma: the PRIMARYS study

ea0032p924 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Endoscopic transsphenoidal surgery for acromegaly: assessing the surgical outcome based on current criteria of remission

ea0032p925 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

The influence of octreotide-LAR treatment on glucose homeostasis in acromegaly

ea0032p926 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Somatotropin and IGF1 levels at diagnose and after surgery in acromegalic patients: is it possible to predict the likelihood of cure at diagnosis?

ea0032p927 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Therapeutic response to recombinat somatropin in children with isolated deficiency of GH

ea0032p928 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Thyroid cancer in patients with acromegaly

ea0032p929 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Therapeutic role of dopamine-agonists in ESRF-induced hyperprolactinaemia

ea0032p930 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

A rare case of pituitary infarction in an 11-year-old pre-pubertal girl with pituitary autoantibodies to piccolo

ea0032p931 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Idiopathic isolated ACTH deficiency presenting with severe hyponatraemia

ea0032p932 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Diagnostic features and surgical therapy of acromegalic patients: experience of the last three decades

ea0032p933 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Evaluation of body weight, insulin resistance, leptin and adiponectin levels in premenopausal women with hyperprolactinemia

ea0032p937 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Carbohydrate metabolism in acromegaly and treatment impact

ea0032p938 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Pituitary apoplexy in clinically nonfunctioning pituitary adenomas: experience of a single center

ea0032p939 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Pituitary abscess: a possible cause of hypopituitarism

ea0032p940 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Cushing's disease recurrence after pregnancy

ea0032p941 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Clinical presentation, treatment approach and outcomes of patients with prolactinomas in real-life clinical practice: a single center experience

ea0032p942 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Clinical characteristics of patients with congenital hypopituitarism in advanced age

ea0032p943 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Pituitary abscess after cabergoline treatment of a prolactinoma in a 56 year old male: case report and review of the literature

ea0032p944 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Tuberous sclerosis: an uncommon cause of hyperprolactinemia

ea0032p945 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Hemiparesis and hemiplegia as clinical presentation in subjects with pituitary tumours

ea0032p946 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Relation with carotid intima media thickness and procalcitonin in acromegalic patients

ea0032p947 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

The role of octreotide LAR treatment on BMI in patients with acromegaly

ea0032p948 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Effect of somatotropin and IGF1 secretion on glucose metabolism: diabetic ketoacidosis as first manifestation of acromegaly

ea0032p949 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Prolactinoma: does the size affect the signs?

ea0032p950 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Diagnosis and treatment of a population of acromegalic patients

ea0032p951 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Syndrome of inappropriate antidiuresis due to low dose hydrochlorothiazide use in a patient after transsphenoidal surgery for pituitary adenoma

ea0032p952 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

An acromegalic patient with giant tumor

ea0032p953 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Hyperprolactinemia in women

ea0032p954 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Radiotherapy in the management of pituitary functioning adenomas: a single-center experience

ea0032p955 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Atypical McCune–Albright syndrome associated with GH secreting pituitary adenoma

ea0032p956 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Hyponatremia as a first sign of panhypopituitarism: empty sella

ea0032p957 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Somatotrop adenomas: comparison between men and women in algerian population

ea0032p958 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Non functionning pituitary adenomas

ea0032p959 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Assessment of bone mineral density in patients with Sheehan’s syndrome

ea0032p960 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Giant invasive macroprolactinoma 2: case report

ea0032p961 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Pituitary hyperplasia secondary to primary hypothyroidism in a child with mosaic trisomy 21

ea0032p962 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Can apelin level used as a marker of active and inactive acromegaly?

ea0032p963 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Pasireotide in treatment of Cushing’s disease: our first experience

ea0032p964 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Corticotroph adenoma and fertility

ea0032p965 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Central hypothyroidism and adjusted thyroxine dose study (CHATS): impact of increasing free thyroxine levels in patients with hypopituitarism

ea0032p966 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

A retrospective-prospective study of the effect of octreotide LAR in acromegalic patients

ea0032p967 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

15th European Congress of Endocrinology

Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>)

Abstract unavailable

BiosciAbstracts